A shift on "pay for delay" - Reopening doors for pharmaceutical competition?

New England Journal of Medicine

Volumn 367, Issue 18, 2012, Pages 1681-1683

  Hemphill Kraus, Erica J ^a  

^a Squire Patton Boggs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868221224     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1209693     Document Type: Article

References (5)

1. In re K-Dur Antitrust Litigation, No. 10-2077 at 11-13 (3d Cir. July 16, 2012) (http://www.ca3.uscourts.gov/opinarch/102077p.pdf).
2. Andrx Pharms., Inc. v. Biovail Corp. Int'l, 256 F.3d 799 (D.C. Circ. 2001).
3. In re Cardizem CD Antitrust Litig., 332 F.3d 896 (6th Cir. 2003).
4. In re Tamoxifen Citrate Antitrust Litig., 466 F.3d.
5. Schering-Plough Corp. v. FTC, 402 F.3d 1056 (11th Cir. 2005).